Showing 4791-4800 of 8223 results for "".
- DermWire Exclusive: Meet Allē, Allergan’s Upgraded Patient Loyalty Programhttps://practicaldermatology.com/news/dermwire-exclusive-meet-alle-allergans-upgraded-patient-loyalty-program/2460244/Allergan’s Brilliant Distinctions customer loyalty program is getting a facelift in honor of its 2nd decade. The program is smarter, faster and now goes by Allē. It’s much more than a new name, shares Carrie Strom, Allergan’s Senior Vice President o
- DermTech’s Pigmented Lesion Assay Receives Medicare Coveragehttps://practicaldermatology.com/news/dermtechs-pigmented-lesion-assay-receives-medicare-coverage/2460241/The Medicare Administrative Contractor Palmetto GBA MolDx issued a final local coverage determination for DermTech, Inc.'s Pigmented Lesion Assay (PLA). The PLA test is used to help rule out primary cutaneous melanoma and guide biopsy decisions of melanocytic skin lesions with one or more cli
- Avita Medical Receives U.S. FDA Investigational Device Exemption Approval of Clinical Feasibility Study to Evaluate RECELL System in Vitiligohttps://practicaldermatology.com/news/avita-medical-receives-us-fda-investigational-device-exemption-approval-of-clinical-feasibility-study-to-evaluate-recell-system-in-vitiligo/2460240/The U.S. Food and Drug Administration (FDA) approved AVITA Medical’s Investigational Device Exemption (IDE) application to conduct a feasibility study evaluating the safety and effectiveness of the RECELL Autologous Cell Harvesting Device (RECELL System) for repigmentation of depigmen
- FDA Approves Ortho Dermatologic’s Arazlo Lotion for Acnehttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-arazlo-lotion-for-acne/2460238/The FDA has approved the New Drug Application for ARAZLO (tazarotene) Lotion, 0.045%, for the topical treatment of acne vulgaris in patients nine years of age and older. Ortho Dermatologic’s ARAZLO is the first tazarotene acne treatment available in a lotion form,
- Ortho Dermatologics Expands Solta Medical Team with New Hireshttps://practicaldermatology.com/news/ortho-dermatologics-expands-solta-medical-team-with-new-hires/2460237/Ortho Dermatologics is staffing up its Solta Medical business unit. The new appointments include the following: Liz Newman, General Manager, Solta, North America Newman first joined Solta in January 2018 as se
- Daavlin, HealthLens Partner to Increase Phototherapy Accesshttps://practicaldermatology.com/news/daavlin-healthlens-partner-to-increase-phototherapy-access/2460232/Daavlin, a leading U.S. manufacturer of phototherapy units, is teaming up with HealthLens to increase access to phototherapy via teledermatology. Appointment wait times for dermatology services have increased by 46 percent since 2009, according to
- Proscia and Johns Hopkins School of Medicine Collaborate to Bring AI Applications to High-Impact Diseases and Specialties in Pathologyhttps://practicaldermatology.com/news/proscia-and-johns-hopkins-school-of-medicine-collaborate-to-bring-ai-applications-to-high-impact-diseases-and-specialties-in-pathology/2460231/Proscia, a provider of AI-enabled digital pathology software, and Johns Hopkins School of Medicine, one of the leading academic medical centers in the US, will collaborate on the development of computational applications that incorporate artificial intelligence (AI) to advance the practice of pat
- Norfolk Dermatologist Recognized for Increasing Accessibility for Patientshttps://practicaldermatology.com/news/norfolk-dermatologist-recognized-for-increasing-accessibility-for-patients/2460227/Dermatologist Abby Van Voorhees, MD, FAAD, is an American Academy of Dermatology Patient Care Hero for her leadership at the Rapid Access Clinic at the Eastern Virginia Medical School Dermatology Practice in Norfolk, Va. The Eastern Virginia Medical School Dermatology practice allo
- NavaDerm Partners Adds Dan Wechsler as Executive Chairmanhttps://practicaldermatology.com/news/navaderm-partners-adds-dan-wechsler-as-executive-chairman/2460225/Dan Wechsler is the new Executive Chairman of NavaDerm Partners, a Northeast-focused dermatology services company and portfolio company of BelHealth Investment Partners, a New York-based healthcare private equity firm. Wechs
- Revance Files BLA for DAXIhttps://practicaldermatology.com/news/revance-files-bla-for-daxi/2460224/Revance Therapeutics, Inc. has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for DaxibotulinumtoxinA for Injection (DAXI) in the treatment of moderate to severe glabellar lines. Under the current Pres